SCHEMBL1891968

SCHEMBL1891968

COc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)nc4)nc3Cl)c2c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.69
CYP3A4 P08684 14/20 0.68
CYP2C19 P33261 4/20 0.60
CSF1R P07333 3/20 0.58
CYP2C9 P11712 7/20 0.56
CYP2D6 P10635 1/20 0.48
KIT P10721 3/20 0.47
KDR P35968 3/20 0.47
FLT3 P36888 3/20 0.47
LCK P06239 1/20 0.47
PGR P06401 1/20 0.47
CHRM2 P08172 1/20 0.47
HTR1A P08908 1/20 0.47
ADRA2A P08913 1/20 0.47
PDGFRB P09619 1/20 0.47
ADORA3 P0DMS8 1/20 0.47
CHRM1 P11229 1/20 0.47
PDGFRA P16234 1/20 0.47
FLT1 P17948 1/20 0.47
DRD1 P21728 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1886367 0.92 CYP3A4 (0.80) CYP1A2CYP3A4CYP2C19CSF1RCYP2C9
SCHEMBL1893239 0.91 CYP1A2 (0.83) CYP1A2CYP3A4CYP2C19CSF1RCYP2C9
SCHEMBL12304376 0.89 CYP3A4 (0.67) CYP1A2CYP3A4CYP2C19CSF1RCYP2C9
SCHEMBL1890622 0.89 CYP3A4 (0.76) CYP1A2CYP3A4CYP2C19CSF1RCYP2C9
SCHEMBL1887435 0.88 CYP3A4 (0.82) CYP1A2CYP3A4CYP2C19CSF1RCYP2C9
SCHEMBL1888172 0.86 CYP1A2 (0.68) CYP1A2CYP3A4CYP2C19CSF1RCYP2C9
SCHEMBL1891318 0.85 CYP1A2 (0.69) CYP1A2CYP3A4CYP2C19CSF1RCYP2C9
SCHEMBL1882109 0.84 CYP2C9 (0.68) CYP1A2CYP3A4CYP2C19CSF1RCYP2C9
SCHEMBL1895407 0.83 CYP3A4 (0.80) CYP1A2CYP3A4CYP2C19CSF1RCYP2C9
SCHEMBL1891873 0.82 CYP3A4 (0.81) CYP1A2CYP3A4CYP2C19CSF1RCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4295912-A2 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR Daiichi Sankyo, Inc. (US) 2023-12-27 EP disclosed
US-9096593-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2015-08-04 US disclosed
US-9096593-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2015-08-04 US disclosed
US-20140045840-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. (US) 2014-02-13 US disclosed
US-20140045840-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. (US) 2014-02-13 US disclosed
EP-2496086-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR Plexxikon, Inc. (US) 2012-09-12 EP disclosed
WO-2011057022-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. (US) 2011-05-12 WO disclosed
WO-2011057022-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. (US) 2011-05-12 WO disclosed
US-20110112127-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. 2011-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112127-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR KIT, FLT3, BRAF CYP1A2 4590/4885CYP3A4 3717/4885CYP2C19 4018/4885
US-20140045840-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR KIT, FLT3, BRAF CYP1A2 4590/4885CYP3A4 3717/4885CYP2C19 4018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.